We are happy to announce a new collaboration between Rapidemic and the Maastricht UMC+, the national reference center for Chlamydia and Care And Public Health Research Institute (CAPHRI). The collaboration project is co-funded by PPP Subsidy awarded by Top Sector Life Sciences & Health, Health~Holland to stimulate public-private partnerships.

The two groups have joined forces to fast-track the development and validation of Rapidemic’s first product for on-the-spot diagnosis of highly prevalent sexually transmitted infections.

Violette Defourt, CEO Rapidemic, states « The group of Petra Wolffs at the MUMC is pioneering national and international STI research in public health and molecular diagnostics. We’re excited about the prospect of bridging excellence with innovation together, and are grateful for the trust and support of Health Holland. »